All the news Showing 10 of 66 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Inexpensive interventions can boost engagement with key stages of viral hepatitis care continuum Michael Carter / 14 October 2016 Several cheap interventions can significantly boost engagement with the continuum of care for viral hepatitis, a systematic literature review and a series of meta-analyses published in The Lancet Infectious Diseases show. Programmes led by ... 'Step-change in strategy' needed to eliminate HBV as a global health threat Michael Carter / 11 October 2016 Hepatitis B virus (HBV) could be eliminated as a global health threat with a scale-up of vaccination coverage, enhanced efforts to prevent vertical (mother-to-child) transmission and expansion of testing and treatment, according to ... Ongoing hepatitis B virus replication associated with higher mortality for people with HIV Liz Highleyman / 11 August 2016 People with HIV and hepatitis B virus (HBV) co-infection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for prompt treatment, according to an ... Hepatitis B treatment may be linked to colorectal and cervical cancer Liz Highleyman / 10 June 2016 People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have a higher rate of malignancies overall, but did show an increased incidence of colorectal and cervical cancer, underlining the ... Antiviral therapy linked to lower liver cancer and mortality in people with mild hepatitis B Liz Highleyman / 17 May 2016 Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver ... Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys Liz Highleyman / 18 April 2016 The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with fewer detrimental effects on bone and kidney biomarkers, ... HIV/HBV co-infection linked to worse immune recovery and death, but tenofovir improves outcomes Liz Highleyman / 12 April 2016 HIV-positive people with hepatitis B virus (HBV) co-infection had impaired CD4 cell recovery after starting antiretroviral therapy (ART) and a higher risk of death than those without hepatitis B, but use of ... Selected patients with chronic HBV may be able to discontinue antiviral treatment and maintain virological control Michael Carter / 29 March 2016 A substantial proportion of people receiving oral antiviral treatment for hepatitis B virus (HBV) may be able to achieve durable virological remission after the withdrawal of therapy, investigators report in Hepatology. Researchers conducted a ... Using interferon with hepatitis B antivirals raises likelihood of HBsAg loss Liz Highleyman / 15 June 2015 Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate ... Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... ← Prev1...23456...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds